Get the Stockscreener App
279.20
2.67%
7.26
After Hours:
283.06
3.86
+1.38%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $279.20, with a volume of 1.80M.
It is up +2.67% in the last 24 hours and up +8.95% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$271.94
Open:
$281.9
24h Volume:
1.80M
Relative Volume:
2.01
Market Cap:
$40.94B
Revenue:
$5.02B
Net Income/Loss:
$1.31B
P/E Ratio:
31.34
EPS:
8.91
Net Cash Flow:
$1.56B
1W Performance:
+1.47%
1M Performance:
+8.95%
6M Performance:
+18.21%
1Y Performance:
+30.13%
1-Day Range:
$271.11
$281.90
1-Week Range:
$270.87
$281.90
52-Week Range:
$199.92
$281.90
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
279.20 | 39.87B | 5.02B | 1.31B | 1.56B | 8.91 |
|
ISRG
Intuitive Surgical Inc
|
483.12 | 172.46B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
176.37 | 51.09B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.87 | 43.30B | 9.93B | 1.12B | 1.58B | 2.25 |
|
WST
West Pharmaceutical Services Inc
|
239.26 | 17.20B | 2.90B | 467.20M | 306.90M | 6.37 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Why Capstone Copper, Flight Centre, ResMed, and SKS shares are pushing higher today - MSN
ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings - Benzinga
ResMed (RMD) Stock Is Up, What You Need To Know - FinancialContent
ResMed (RMD) Price Target Increased by Piper Sandler to $270 - GuruFocus
ResMed's Moat Is Underpinned by Switching Costs and Intangible Brand Assets - Morningstar
ResMed (RMD) Price Target Increased by Baird Analyst Amid Strong Fundamentals - GuruFocus
ResMed (RMD) Price Target Raised by UBS Analyst - GuruFocus
ResMed (RMD) Sees Price Target Raised by Keybanc Analyst | RMD S - GuruFocus
A Quick Look at Today's Ratings for ResMed(RMD.US), With a Forecast Between $298 to $325 - 富途牛牛
ResMed Inc. (NYSE:RMD) Q4 2025 Earnings Call Transcript - Insider Monkey
ResMed (RMD) Price Target Raised by KeyBanc on Growth Outlook - GuruFocus
ResMed price target raised to $325 from $285 at UBS - TipRanks
How volatile is ResMed Inc. stock compared to the marketPre Market Planner For Beginners - jammulinksnews.com
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb - TradingView
Earnings call transcript: ResMed’s Q4 2025 shows strong EPS, stock dips post-call - Investing.com
ResMed Inc (RMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions - Yahoo.co
Global demand helps push ResMed shares to record high - inkl
Resmed Inc. Reports Strong Q4 2025 Earnings Growth - TipRanks
Resmed Australia shares hit record high on strong earnings - Investing.com
Resmed Australia shares hit record high on strong earnings By Investing.com - Investing.com India
ResMed outlines 61%–63% gross margin target for FY26 while ramping up share buybacks and dividend - MSN
ResMed: Result 2025 - intelligentinvestor.com.au
ResMed's ASX shares hit record on earnings beat, but is the future still bright? - Livewire Markets
ResMed: Fiscal Q4 Earnings Snapshot - Norwalk Hour
ResMed Inc. 2025 Q2ResultsEarnings Call Presentation (NYSE:RMD) - Seeking Alpha
Resmed posts Wall Street beat in Q2 - MassDevice
ResMed share price hits record high on strong FY25 results - The Motley Fool Australia
ResMed Q4 Earnings: Key Metrics Highlight Revenue and EPS Growth - AInvest
ResMed Q4 FY2025 slides reveal 10% revenue growth, shift to net cash position By Investing.com - Investing.com South Africa
Here's What Key Metrics Tell Us About ResMed (RMD) Q4 Earnings - Yahoo Finance
Resmed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ResMed earnings beat by $0.07, revenue fell short of estimates - Investing.com Canada
ResMed (RMD) Surpasses Q4 Earnings and Revenue Estimates - Nasdaq
ResMed (NYSE:RMD) Surprises With Q2 Sales - Yahoo Finance
ResMed Reports Strong Q4 Earnings, Surpassing Wall Street ExpectationsNews and Statistics - IndexBox
Resmed Announces Increased Quarterly Dividend - TipRanks
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
Resmed beats quarterly profit estimates on strong demand for sleep devices - TradingView
ResMed Inc Reports Q4 Revenue of $1.3 Billion, Slightly Missing Estimates; EPS Growth of 23% - GuruFocus
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025 - The Manila Times
RMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ResMed Inc. - ACCESS Newswire
When is ResMed Inc. stock expected to show significant growthFree Stock Data Feed Backed By Experts - jammulinksnews.com
ResMed's 257th High-Volume Rank and Earnings Outlook Signal Strategic Short-Term Opportunities - AInvest
Spot Outliers Like ResMed Early with Money Flows - FXEmpire
ResMed Earnings Preview: Anticipating Growth Amidst Industry TrendsNews and Statistics - IndexBox
Stock Analysis | ResMed OutlookA Mixed Technical Picture Amid Strong Analyst Optimism - AInvest
Ozempic maker Novo Nordisk plunges 22%. What could this mean for Resmed shares? - The Motley Fool Australia
Will ResMed Inc. stock benefit from interest rate changesDay Trading Signals With High Precision Reviewed - metal.it
ResMed (RMD) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD) - Yahoo.co
ResMed stock hits 52-week high at 275.86 USD By Investing.com - Investing.com Canada
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):